Breaking News

Tweet TWEET

Mylan Launches First Generic ORTHO EVRA® Patch

                Mylan Launches First Generic ORTHO EVRA® Patch

PR Newswire

PITTSBURGH, April 16, 2014

PITTSBURGH, April 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has
launched XULANE™ (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35
mcg per day), the generic version of Janssen Pharmaceuticals Inc.'s ORTHO
EVRA®* (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per
day). This product is indicated for the prevention of pregnancy in women who
elect to use a transdermal patch as a method of contraception. Mylan received
final approval from the U.S. Food and Drug Administration (FDA) for its
Abbreviated New Drug Application (ANDA) for this product.

Mylan CEO Heather Bresch commented: "Mylan is proud to continue expanding its
portfolio of transdermal products through the launch of the first generic
Ortho Evra Patch. Mylan's XULANE (Norelgestromin / Ethinyl Estradiol
Transdermal System 150/35 mcg per day), which provides women with a high
quality, affordable treatment option,once again demonstrates Mylan's
commitment to bring to market difficult-to-develop and -manufacture medicines
in support of our mission to expand access to high quality medicine."

ORTHO EVRA had U.S. sales of approximately $152.9 million for the 12 months
ending Dec. 30, 2013, according to IMS Health.

Currently, Mylan has 300 ANDAs pending FDA approval representing $104.5
billion in annual brand sales, according to IMS Health. Forty-two of these
pending ANDAs are potential first-to-file opportunities, representing $25.4
billion in annual brand sales, for the 12 months ending December 31, 2013,
according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

SOURCE Mylan Inc.

Website: http://www.mylan.com
Contact: Nina Devlin (Media), 724.514.1968; Kris King (Investors),
724.514.1813
 
Press spacebar to pause and continue. Press esc to stop.